Pa. Jury Returns $3.65 Million Verdict in Actos Bladder Cancer Case




PHILADELPHIA — A jury has returned a verdict of more than $2.3 million in non-economic and compensatory damages and $1.3 million in punitive damages in favor of a Pennsylvania man who alleged that his bladder cancer was caused by Takeda Pharmaceuticals Inc.’s diabetes drug Actos.

After deliberating for eight hours, the Philadelphia Court of Common Pleas jury on Feb. 12 awarded John Kristufek $2 million in non-economic damages and $318,000 in compensatory damages.

On Feb. 13, the jury awarded Kristufek $1.3 million in punitive damages after finding that Takeda had acted with reckless indifference in failing to adequately warn …

FIRM NAMES
  • Kaye Scholer
  • The Miller Firm





UPCOMING CONFERENCES




HarrisMartin's Webinar Series: Depo-Provera CI Litigation

November 04, 2024

MORE DETAILS



HarrisMartin’s Artificial Stone Silicosis Epidemic Litigation Conference

January 10, 2025 - Long Beach, CA
The Westin Long Beach

MORE DETAILS